seri
phosphin
compound
mimick
transit
state
substrat
hydrolys
aminopeptidas
n
ec
synthes
new
compound
potent
inhibitori
activ
ki
valu
nanomolar
rang
deriv
behav
potent
apn
inhibitor
design
date
enzym
inhibitor
phosphin
acid
deriv
resolut
apn
monomer
homodimer
type
ii
membranebound
zinc
exopeptidas
wide
distribut
mammalian
tissu
includ
central
nervou
system
particularli
abund
level
kidney
intestin
lung
vivo
enzym
involv
metabol
angiotensin
iii
brain
peripher
organ
degrad
nociceptin
inactiv
enkephalin
associ
neutral
endopeptidas
nep
furthermor
apn
prove
ident
human
lymphocyt
surfac
cluster
differenti
antigen
behav
receptor
coronavirus
tgev
pig
human
apn
also
report
play
import
role
invas
metastat
tumor
vitro
find
make
enzym
interest
target
possibl
therapeut
applic
requir
develop
potent
select
inhibitor
apn
exhibit
broad
specif
peptid
ntermin
neutral
basic
amino
acid
alanin
arginin
leucin
sequenc
comparison
sitedirect
mutagenesi
experi
suggest
enzym
mode
zinc
coordin
thermolysin
apn
zinc
coordin
three
residu
two
bistidin
found
consensu
sequenc
glutam
e
bound
residu
ctermin
second
histidin
glutam
consensu
sequenc
act
gener
base
catalysi
littl
known
structur
mechan
action
enzym
show
greatest
effici
apn
around
nm
compound
present
poor
select
versu
aminopeptidas
synthet
apn
inhibitor
develop
analogu
amino
acid
includ
aminohydroxam
aminoboron
acid
aminophosphon
acid
aminoaldehyd
among
select
rel
potent
inhibitor
ki
valu
around
order
improv
apn
inhibit
mercapto
analogu
bestatin
diaminothiol
prepar
unfortun
compound
significantli
increas
apn
recognit
furthermor
peptid
analogu
bear
ketomethylen
hydroxyethylen
bond
ctketoamid
group
shown
icso
rang
non
peptid
inhibitor
also
prepar
aim
obtain
compound
increas
stabil
better
bioavail
howev
ki
valu
found
g
molar
rang
activ
vivo
report
order
design
potent
select
apn
inhibitor
use
concept
transit
state
analogu
capabl
interact
subsit
activ
site
endow
phosphin
group
zinc
ligand
inhibitor
endopeptidas
matrix
metalloendopeptidas
contain
phosphin
acid
zinc
ligand
alreadi
describ
type
molecul
free
amino
group
aminopeptidas
inhibit
report
first
time
aaminophosphin
acid
bear
hydrophob
side
chain
interact
subsit
synthes
found
inhibit
apn
molar
rang
coupl
caminophosphin
acid
analogu
dipeptid
pheph
shown
recogn
effici
subsit
apn
provid
new
phosphino
peptid
potent
inhibitori
activ
toward
apn
describ
gener
scheme
synthesi
inhibitor
report
figur
benzyloxycarbonyl
z
protect
phosphin
acid
af
prepar
follow
previous
report
method
coupl
af
phenylalanin
methyl
ester
led
af
two
step
deprotect
gave
compound
latter
obtain
mixtur
four
stereoisom
due
presenc
two
unresolv
asymmetr
carbon
prepar
hplc
yield
gener
two
fraction
contain
two
isom
ab
cd
firstli
test
apn
without
separ
first
step
inhibitori
activ
variou
ctaminophosphin
acid
contain
hydrophob
side
chain
measur
pig
kidney
apn
purchas
boehring
compar
correspond
baminothiol
howev
compound
effici
correspond
aminoacid
analogu
ctaminohydroxam
aaminophosph
shown
suggest
phosphin
moieti
would
interest
altern
thiol
group
zn
chelat
catalyt
site
apn
second
step
inhibitori
potenc
compound
design
interact
sj
subsit
apn
measur
tabl
ki
valu
compound
slightli
increas
compar
correspond
oaminophosphin
acid
howev
accord
presenc
two
unresolv
asymmetr
center
compound
could
assum
occup
subsit
led
gain
affin
one
order
magnitud
data
confirm
effici
phosphin
group
zinc
ligand
apn
inhibit
also
demonstr
necess
interact
subsit
apn
optim
inhibit
enzym
third
step
compound
contain
c
termin
phenylalanin
posit
test
case
mixtur
two
stereoisom
ab
show
nanomolar
inhibitori
potenc
direct
comparaison
indic
fold
increas
activ
observ
due
subsit
occup
two
result
could
also
underlin
direct
relationship
inhibitori
potenc
ctaminophosphin
acid
report
tabl
phosphin
peptid
report
tabl
instanc
compound
contain
methyl
group
posit
r
one
activ
inhibitor
correspond
ctaminophosphin
acid
less
effici
seri
ki
valu
invers
situat
occur
methionin
side
chain
ii
compound
test
mixtur
isom
ab
significantli
activ
cd
show
larg
import
absolut
configur
asymmetr
carbon
consequ
isol
potent
isom
complet
separ
perform
compound
recristal
ctmethylbenzylamin
salt
ctaminophosphin
acid
la
r
le
r
chzph
led
r
isom
follow
synthet
pathway
report
figur
pure
isom
led
infin
format
compound
mixtur
isom
b
differ
absolut
configur
second
asymmetr
carbon
isom
b
easili
separ
prepar
hplc
isom
lib
activ
tabl
stereochem
assign
r
determin
ih
nmr
spectrocopi
ki
valu
mean
sem
three
independ
experi
perform
triplic
apn
activ
measur
use
aiapna
substrat
apa
activ
measur
use
giuna
substrat
apb
activ
measur
use
arg
pna
substrat
determin
select
inhibitor
toward
target
enzym
test
zn
metallopeptidas
famili
select
factor
obtain
versu
apa
higher
versu
apb
tabl
result
consist
prefer
latter
enzym
acid
basic
residu
posit
respect
best
inhibitor
also
test
two
endopeptidas
nep
ace
inde
account
hydrophob
charact
activ
site
synthes
phosphin
compound
could
inhibit
effici
physiolog
enzym
howev
select
factor
obtain
show
either
presenc
free
amino
group
lib
unfavour
nep
ace
recognit
hydrophob
side
chain
inhibitor
optim
interact
two
endopeptidas
high
select
factor
also
obtain
cytosol
leucin
aminopeptidas
lap
whose
mechan
action
differ
gluzincin
due
high
affin
toward
apn
select
versu
metalloenzym
phosphin
inhibitor
could
use
complet
charater
biochem
pharmacolog
properti
apn
synthesi
radiolabel
analogu
underway
laboratori
conclus
develop
new
seri
potent
select
apn
inhibitor
design
transit
state
analogu
interact
subsit
enzym
approach
led
potent
inhibitor
apn
report
date
ki
valu
nanomolar
rang
moreov
compound
could
modifi
gener
new
dual
inhibitor
neutral
endopeptidas
nep
apn
critic
point
design
dual
inhibitor
optim
recognit
apn
